Pseudomonas

(redirected from Pseudomonas infections)
Also found in: Dictionary, Thesaurus, Medical.
Related to Pseudomonas infections: Klebsiella infections

Pseudomonas

A genus of gram-negative, nonsporeforming, rod-shaped bacteria. Motile species possess polar flagella. They are strictly aerobic, but some members do respire anaerobically in the presence of nitrate. Some species produce acids oxidatively from carbohydrates; none is fermentative and none photosynthetic.

Members of the genus Pseudomonas cause a variety of infective diseases; some species cause disease of plants. One species, P. mallei, is a mammalian parasite, and is the causative agent of glanders, an infectious disease of horses that occasionally is transmitted to humans by direct contact. Pseudomonas aeruginosa is the most significant cause of hospital-acquired infections, particularly in predisposed patients with metabolic, hematologic, and malignant diseases. The spectrum of clinical disease ranges from urinary tract infections to septicemia, pneumonia, meningitis, and infections of postsurgical and posttraumatic wounds. See Meningitis, Pneumonia

Pseudomonas

[‚süd·ə′mōn·əs]
(microbiology)
A genus of gram-negative, motile, non-spore-forming, rod-shaped bacteria that cause a variety of infectious diseases in animals and humans (such as glanders and melioidosis) and in plants.
References in periodicals archive ?
According to the (https://www.cdc.gov/hai/organisms/pseudomonas.html) Centers for Disease Control and Prevention , pseudomonas infection is a disease caused by bacterium from the genus pseudomonas, which are strains of bacteria found mostly in the environment including soil, water, and plants.
THERE is a way to cure the deadly pseudomonas infection.
A controlled clinical trial of tobramycin for the treatment of Pseudomonas infection in cystic fibrosis patients less than 6 years old had such dramatic early results that the study was stopped early, after just 21 patients had been treated.
This financing complements the recent CARB-X grant of up to $8,9 million awarded to Antabio in July 2017 to support the company's Elastase Inhibitor program (PEI) for the treatment of chronic Pseudomonas infections in Cystic Fibrosis patients.
(1.) Lari AR, Honar HB, Alaghehbandan R: Pseudomonas infections in Tohid Burn Center, Iran.
The presence of Pseudomonas infection in burn patients in the late 1950s and early 1960s, considered by many to be a burn specific aberration, was validated by subsequent experience to have been an epidemiological premonition of infection in other critically ill patients.(8) The pattern of infection differs from hospital to hospital; the bacterial flora of infected wound may change considerably during the healing period.(9) Emergence of multi drug resistant pathogens in hospital setting has seriously constrained the available therapeutic options.
[ClickPress, Wed Jul 03 2013] Global Markets Direct's, 'Pseudomonas Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline.
* A review of the Pseudomonas Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Today, the best drugs for empiric treatment of Pseudomonas infections are either third-generation fluoroquinolones, such as gatifloxacin or moxifloxacin, or a third-generation cephalosporin, she said.
When ViMs were transferred to unvaccinated mice with chemotherapy-depleted neutrophils, they were protected from lethal Pseudomonas infections.